Political Donations and Lobbying, USA
FTC Price Fixing Case Against Mylan
The Federal Tade Commission accused Mylan and other companies in
1998 of orchestrating an illegal price increase that exceeded
2,000 percent for the generic drugs lorazepam and clorazepate,
both used to treat Alzheimer’s disease and anxiety.
- November 29, 2000. US District Court for the District of Columbia.
Federal Trade Commission v. Mylan Laboratories, Inc., et al: Order and Stipulated Permenant Injunction.
- November 29, 2000. Federal Trade Commission press release.
FTC Reaches Record Financial Settlement To Settle Charges of
Price-fixing in Generic Drug Market.
Information Page for the Lorazepam/Clorazepate Settlement set
up by Rust Consulting, which has been hired to administer the settlement.
- State Attorney Generals' Offices press releases.
- December 21, 1998, FTC Press Release,
Mylan, Nation's Second Largest Generic Drug Maker,
Restraint of Trade, Conspiracy & Monopolization:
Illegal Conduct Resulted in Price Increases of up
to 3000 Percent for Two Anti-anxiety Drugs,
FTC Alleges; Agency to Seek $120 Million in
The illegal activity allowed Mylan to dramatically increase the price of
the two drugs used by
millions of Americans, the Commission alleged. In
January of this year, the company raised the wholesale
price of clorazepate from $11.36 to approximately
$377.00 per bottle of 500 tablets. And, in March, the
wholesale price of lorazepam went from $7.30 for a
bottle of 500 tablets to approximately $190.00
- December 21, 1998, Mylan Press Release:
Mylan Denies FTC Charge. Mylan also issued other press
December 22, 1998 and
December 23, 1998.
- December 22, 1998, Cambrex Press Release,
Cambrex Corporation Responds to FTC Charges.
- A number of law suits have been filed in this matter
by state attorney generals and consumer class action cases.